<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443078</url>
  </required_header>
  <id_info>
    <org_study_id>11-106</org_study_id>
    <nct_id>NCT01443078</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)</brief_title>
  <official_title>Phase II Trial of Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test a new approach to the use of standard drugs before
      surgery in patients with lung cancer. This study will find out what effects, good and/or bad,
      that this approach has on the cancer.

      It is routine to give chemotherapy prior to surgery in patients with this type of lung
      cancer, to help keep it from coming back. It is also routine to perform a special type of
      scan called a PET scan. This PET scan measures how active a cancer is by use of a special
      tracer made out of sugar. In this study, all patients will have a PET scan and then be
      treated with standard chemotherapy drugs, either pemetrexed and cisplatin if the cancer is a
      &quot;non-squamous&quot; cancer or gemcitabine and cisplatin if the cancer is a squamous cancer. In
      rare cases, the doctor will decide to give carboplatin instead of cisplatin. In most
      patients, a repeat PET scan will show that the tumor is decreasing and they will complete
      standard chemotherapy then go on to have surgery.

      In some patients, a repeat PET scan will show that the tumor has not decreased enough. For
      these patients, the routine practice is to proceed with surgery. This research study will
      test whether switching from the standard treatment of pemetrexed and cisplatin or gemcitabine
      and cisplatin to a different treatment called vinorelbine and docetaxel is safe and
      effective. Vinorelbine and docetaxel are also standard chemotherapy drugs which work in a
      different way than pemetrexed or gemcitabine and cisplatin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PERCIST Partial Metabolic Response</measure>
    <time_frame>2 years</time_frame>
    <description>The primary endpoint was partial metabolic response after 2 cycles of &quot;switch&quot; therapy as assessed by PERCIST (SUVmax decrease ≥30% using the pre-switch scan as new baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>(FDG PET and CT), rate of pathologic down-staging, rate of pathologic response, and stage-specific disease free and overall survival in patients with resectable Stage Ib-IIIa &quot;non-squamous&quot;, NSCLC treated with neoadjuvant pemetrexed + cisplatin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>pemetrexed plus cisplatin, vinorelbine and docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase 2 clinical trial for patients with clinical Stage IB-III resectable and operable non-small cell lung cancer, evaluating whether the switch to an alternative, non-platinum neoadjuvant chemotherapy is safe and effective in patients who do not respond to neoadjuvant platinum-based chemotherapy. Those who fail to respond to platinum-based chemotherapy will be switched to the alternative neoadjuvant chemotherapy vinorelbine 45 mg/m2 and docetaxel 45 mg/m2 on day 1 followed by pegylated filgrastim on day 2, repeated every 2 weeks for 4 doses, followed by repeat FDG PET and CT scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <arm_group_label>pemetrexed plus cisplatin, vinorelbine and docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>pemetrexed plus cisplatin, vinorelbine and docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>pemetrexed plus cisplatin, vinorelbine and docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <arm_group_label>pemetrexed plus cisplatin, vinorelbine and docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine Tartrate</intervention_name>
    <arm_group_label>pemetrexed plus cisplatin, vinorelbine and docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>pemetrexed plus cisplatin, vinorelbine and docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic confirmation of NSCLC at MSKCC

          -  Stages IB, IIA, IIB, IIIA or IIIB NSCLC

          -  Primary tumor must measure ≥ 2 cm on CT imaging (per PERCIST guidelines)

          -  Primary tumor must be FDG-avid with an SUVmax &gt;4.5 (to be consistent with PERCIST
             guidelines)

          -  Patients must be candidates for resection with curative intent

          -  Age ≥ 18 years

          -  Karnofsky performance status ≥ 70%

          -  Normal bone marrow function

          -  leukocytes ≥ 3,000/μl

          -  absolute neutrophil count ≥ 1,500/μl

          -  platelets ≥100,000/μl

          -  hemoglobin ≥9gm/dl.

          -  Adequate hepatic function

          -  Total bilirubin ≤1.5 x ULN

          -  AST ≤ 1.5 x UNL, ALT ≤ 1.5 x ULN

          -  Alkaline phosphatase ≤ 1.5x ULN

          -  Women of childbearing age must have a negative pregnancy test

          -  Men and women of childbearing potential must be willing to use effective contraception
             while on treatment and for at least 3 months thereafter

          -  Patients must have the ability to understand and the willingness to sign a written
             informed consent document

        Exclusion Criteria:

          -  Patients must not be receiving any other investigational agents

          -  History of myocardial infarction or unstable angina within the past 12 months Patients
             with peripheral neuropathy &gt; grade 1

          -  Other serious illness or medical condition including unstable cardiac disease
             requiring treatment, history of significant neurologic or psychiatric disorders
             (including psychotic disorders, dementia, or seizures), or active uncontrolled
             infection.

          -  Patients with diabetes mellitus requiring insulin therapy (per PERCIST guidelines)

          -  Patients with third space fluid which cannot be adequately controlled with drainage

          -  Women who are pregnant or breast-feeding

          -  Psychiatric illness or social situation that would limit compliance with study
             requirements

          -  Patients with known HIV infection requiring antiretroviral medications and those with
             AIDS

          -  Baseline subjective hearing deficit, even if it does not require a hearing aid or
             intervention, or interfere with activities of daily living (CTCAE grade 2 or higher)

          -  Baseline renal function &lt;60 ml/min as calculated by the equation of Cockcroft and
             Gault using the patient's age, weight (kg), and serum creatinine (mg/dl).

          -  Congestive heart failure with New York Heart Association functional classification &gt;
             II, characterized by fatigue, dyspnea or other symptoms which limit activities of
             daily life.

        Selection of Pemetrexed versus Gemcitabine: Patients treated with pemetrexed must meet all
        of the following criteria:

          -  Non-squamous histology

          -  Patients must have the ability to interrupt non-steroidal anti-inflammatory drugs
             (NSAIDs) 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days
             following administration of pemetrexed

          -  Patients must have the ability to take folic acid, Vitamin B12, and dexamethasone
             according to protocol

          -  Patient refuses to take cisplatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie E. Chaft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <results_first_submitted>June 29, 2016</results_first_submitted>
  <results_first_submitted_qc>June 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2016</results_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carboplatin</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Pemetrexed (Altima)</keyword>
  <keyword>Taxotere (Docetaxel)</keyword>
  <keyword>Vinorelbine Tartrate (Navelbine)</keyword>
  <keyword>Stage IB-III</keyword>
  <keyword>non squamous</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>11-106</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Patients</title>
          <description>Patients with clinical Stage IB-III resectable and operable non-small cell lung cancer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Responded to neoadjuvant platinum txt</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient had brain mets</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>Patients with clinical Stage IB-III resectable and operable non-small cell lung cancer</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PERCIST Partial Metabolic Response</title>
        <description>The primary endpoint was partial metabolic response after 2 cycles of &quot;switch&quot; therapy as assessed by PERCIST (SUVmax decrease ≥30% using the pre-switch scan as new baseline).</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>Patients with clinical Stage IB-III resectable and operable non-small cell lung cancer</description>
          </group>
        </group_list>
        <measure>
          <title>PERCIST Partial Metabolic Response</title>
          <description>The primary endpoint was partial metabolic response after 2 cycles of &quot;switch&quot; therapy as assessed by PERCIST (SUVmax decrease ≥30% using the pre-switch scan as new baseline).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>(FDG PET and CT), rate of pathologic down-staging, rate of pathologic response, and stage-specific disease free and overall survival in patients with resectable Stage Ib-IIIa &quot;non-squamous&quot;, NSCLC treated with neoadjuvant pemetrexed + cisplatin</description>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>There was not a comparative toxicity analysis done. CTCAE toxicities were collected for all patients. A comparative toxicity of those patients who switched versus those who did not was not seen as clinically relevant. Hematologic toxicities are anticipated with all chemotherapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>Patients with clinical Stage IB-III resectable and operable non-small cell lung cancer</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chaft, Jamie, MD</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-4545</phone>
      <email>ChaftJ@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

